2021
Identification of Risk Factors for Coexisting Sinusitis and Inflammatory Bowel Disease
Rai V, Traboulsi C, Silfen A, Ackerman M, Erondu A, Karpin J, Gulotta G, Rubin D. Identification of Risk Factors for Coexisting Sinusitis and Inflammatory Bowel Disease. Crohn's & Colitis 360 2021, 3: otab054. PMID: 35531367, PMCID: PMC9075692, DOI: 10.1093/crocol/otab054.Peer-Reviewed Original ResearchDuration of diseaseSteroid exposureChronic sinusitis diagnosisRisk of sinusitisSingle-center studyInflammatory bowel diseaseClinical trial dataLogistic regression analysisWilcoxon rank sum testRank sum testSinusitis diagnosisSubsequent sinusitisExtraintestinal manifestationsMaintenance therapyIBD diagnosisAdverse eventsBowel diseaseUC diagnosisMultivariable analysisRisk factorsSinusitisPatientsSubsequent diseaseTrial dataYounger age
2019
Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid‐refractory ulcerative colitis
Ollech J, Dwadasi S, Rai V, Peleg N, Normatov I, Israel A, Sossenheimer P, Christensen B, Pekow J, Dalal S, Sakuraba A, Cohen R, Rubin D. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid‐refractory ulcerative colitis. Alimentary Pharmacology & Therapeutics 2019, 51: 637-643. PMID: 31875986, DOI: 10.1111/apt.15616.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, Monoclonal, HumanizedCalcineurin InhibitorsColitis, UlcerativeDrug Administration ScheduleDrug ResistanceFemaleFollow-Up StudiesHumansInduction ChemotherapyMaintenance ChemotherapyMaleProgression-Free SurvivalRetrospective StudiesSeverity of Illness IndexSteroidsTreatment OutcomeYoung AdultConceptsSevere steroid-refractory ulcerative colitisSteroid-refractory ulcerative colitisCalcineurin inhibitorsInduction therapyMaintenance therapyUlcerative colitisVedolizumab initiationMedian timeWeek 14Colectomy-free survival ratesSevere steroid-refractory colitisColectomy-free survivalSteroid-refractory colitisVedolizumab maintenance therapyInduction of remissionSerious adverse eventsSevere ulcerative colitisRetrospective observational studyEnd of inductionBiochemical remissionVedolizumab discontinuationClinical remissionPrimary endpointSecondary endpointsAdult patients